The Connection Between Rosacea and Dry Eye Disease
Periocular inflammatory conditions, such as Rosacea, affect millions every year. Predominantly a skin condition, Rosacea can have a significant impact on an individual’s quality of life with visible symptoms such as redness, swelling and irritation.
Inflammatory skin diseases, like Rosacea, are characterised by the formation of vascular abnormalities, which release inflammatory agents. When occurring in proximity to the eyes, these mediators propagate via the orbital vasculature to the eyelids, often resulting in inflammation of the eyelids, which, in turn, may trigger the ocular complications such as Meibomian Gland Dysfunction (MGD)1,2.
MGD is the most common type of Dry Eye Disease (DED)3 and occurs when the glands are blocked due to bacterial loads damaging the lipid layer of the eye. This then increases the osmolarity of the tear film and leads to dry, red, itchy and burning of the eye. A multi-factorial in nature, DED is particularly difficult to treat effectively, as it triggers a vicious cycle of inflammation.
Lumenis’ revolutionary M22 Optima IPL device offers a drug-free, drop-free alternative to treating the root cause of DED – chronic inflammation. Unlike conventional treatments, Optima IPL uses advanced Intense Pulsed Light (IPL) and Lumenis’ unique Optimal Pulse Technology (OPT™) to deliver a controlled amount of intense pulsed light to the periocular region.
The Optima M22 IPL breaks the vicious cycle of inflammation in multiple points4,5, addressing Dry Eye Disease due to MGD from multiple angles as it reduces inflammatory mediators6,7, alleviating the abnormal blood vessels perpetuating the inflammation8,9 and decreasing the number of Demodex mites which are stimulating infection leading to inflammation10. The Optima IPL also works to restore homeostasis in DED, as it reduces the tear film osmolarity back to normal levels4,5 and restores meibomian gland’s morphology and functionality7.
With every pulse of light, this energy-based therapy controls the inflammatory process and displaces the need for medications, offering long-lasting results.
Explore The HUB on demand to discover more about harnessing the power of Optima M22 IPL. Tune in to virtual seminars as leading global experts discuss DED as a prominent concern across the medical industry. Find out more.
- De Paiva et al. (2006) Am J Ophthalmol 141(3):438-45
- Solomon et al.(2004) Ocul Surf 2(1):34-44
- Lemp et al. (2012) Cornea 31(5)
- Toyos & Briscoe (2016) J Clin Exp Ophthalmol. 7(6)
- Dell et al. (2017) Clin Ophthalmol 11:817- 827
- Yin et al. (2018) Curr Eye Res 43(3):308-13
- Prieto et al. (2002) Lasers Surg Med 30(2):82-5